Eight late-stage drugs signal a new era in generalized myasthenia gravis treatment with improved efficacy and safety.

The generalized myasthenia gravis (gMG) market is poised for significant change with eight promising late-stage drugs advancing clinical development. These include novel therapies like IMVT-1402, Telitacicept, FABHALTA, and others that offer targeted mechanisms such as FcRn inhibition, B-cell modulation, and complement system blockade. The market, valued at $5.9 billion in 2025, is expected to grow strongly due to better diagnosis, biologic adoption, and patient access. Despite progress, unmet needs remain for faster, safer, and more effective treatments, especially for refractory patients, making these new drugs potential game-changers in gMG management.